SCHEMBL3223889

SCHEMBL3223889

NCC1CCN(CC(=O)Nc2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
HTT P42858 2/20 0.59
ALDH1A1 P00352 4/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP2C9 P11712 1/20 0.56
MAPT P10636 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
GAA P10253 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
SMYD3 Q9H7B4 1/20 0.50
CYP1A2 P05177 1/20 0.50
RECQL P46063 1/20 0.50
CCR3 P51677 1/20 0.49
NAMPT P43490 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4577386 0.84 LMNA (0.66) LMNAHTTALDH1A1MAPTSMN1; SMN2
SCHEMBL4750163 0.83 LMNA (1.00) LMNAHTTALDH1A1CYP2D6CYP2C19
SCHEMBL4578026 0.82 CCR3 (0.69) LMNAHTTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3224693 0.82 NPC1 (0.63) LMNAHTTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL22407654 0.82 LMNA (0.97) LMNAHTTALDH1A1CYP2D6CYP2C19
SCHEMBL15092656 0.82 LMNA (0.97) LMNAHTTALDH1A1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL3211216 0.81 NPC1 (0.62) LMNAHTTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL18040093 0.80 LMNA (0.78) LMNAHTTALDH1A1MAPTSMN1; SMN2
SCHEMBL6323061 0.80 LMNA (0.78) LMNAHTTALDH1A1MAPTSMN1; SMN2
SCHEMBL3207988 0.79 ALDH1A1 (0.65) LMNAALDH1A1CYP2C19CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519139-B2 Indazolamides with analgesic activity Aziende Chimeche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2013-08-27 US disclosed
EP-1594859-B1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY ACRAF (IT) 2010-06-23 EP disclosed
US-20100048907-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO S.P.A. (IT) 2010-02-25 US disclosed
US-7632849-B2 N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)- 1-(1-methylethyl)-1H-indazole-3-carboxamide; antiarthritic agents; rheumatic diseases; osteoarthritis; fibromyaleia;anticarcinogenic agents, pain; neuropathic pain; immunoincompetance; trauma; antiischemic agents; multiple sclerosis AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2009-12-15 US disclosed
US-20060052417-A1 Indazolamides with analgesic activity AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2006-03-09 US disclosed
EP-1594859-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2005-11-16 EP disclosed
WO-2004074275-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048907-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY TRPV1, CA2, TRPV2 LMNA 2839/4885HTT 2362/4885ALDH1A1 571/4885
US-20060052417-A1 Indazolamides with analgesic activity P2RX7, P2RX3, P2RX1 LMNA 1830/4885HTT 1696/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.